Tyrosine kinase inhibitors for mutant type FLT3 such as gilteritinib, quizartinib and midostaurin efficiently suppress the growth of FLT3 mutation positive AML cells in preclinical studies and prolong survival of AML patients in clinical trials [20]. This evidence concerns the gene FLT3 and acute myeloid leukemia.